Search
Obeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigational[A192786] Obeticholic acid is a farnesoid-X receptor (FXR) agonist used to treat this condition, possibly allowing for increased survival. … The NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636]
Categories: Farnesoid X Receptor Agonist, Farnesoid X Receptor AgonistsOxybutynin
go.drugbank.com/drugs/DB01062ApprovedInvestigationalOveractive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. … Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.
Products: LYRINELTABLETAS DE 10 MG, LYRINEL TABLETAS DE 15 MGMavacamten
go.drugbank.com/drugs/DB14921ApprovedInvestigationalIt received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. … [A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471]
Products: CAMZYOS® 2.5MG CAPSULAS DURAS DE LIBERACIÓN INMEDIATA.Ganaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigational[L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636] … [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment
Categories: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive ModulatorMenadione
go.drugbank.com/drugs/DB00170ApprovedNutraceuticalA synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.
Zinc sulfate, unspecified form
go.drugbank.com/drugs/DB14548ApprovedZinc sulfate is a common zinc supplement in parenteral nutrition.
Mixtures: Se-Tan PLUS, Aqua De Folli Hair BoosterPantoprazole
go.drugbank.com/drugs/DB00213ApprovedInvestigationalAs the binding of pantoprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, pantoprazole's duration of antisecretory effect persists … This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus.
Products: Pantoprazole T, Mylan-pantoprazole TDexamethasone
go.drugbank.com/drugs/DB01234ApprovedInvestigationalVet approved[L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724] Dexamethasone was granted FDA approval on 30 October 1958. … Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic
Mixtures: TQ OFTAMOX D UD®, TQ OFTAMOX® D UDCategories: Corticosteroid Hormone Receptor AgonistsNefazodone
go.drugbank.com/drugs/DB01149ApprovedWithdrawnDrug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to … On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Adrenergic alpha-1 Receptor AntagonistsCaroxazone
go.drugbank.com/drugs/DB09254ApprovedWithdrawnHowever, it presents a five-fold preference for the MAO-B subtype. … Caroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome